SCHIZOPHRENIA AND ASSOCIATED DISORDERS

- Schizophrenia is a psychotic mental disorder of unknown aetiology characterised by disturbances in thinking, mood and behaviour
 - o Thinking disturbance is manifested by:
 - Distortion of reality
 - Sometimes with delusions and hallucinations
 - Fragmentation of associations that results in characteristic disturbance of speech
 - Disturbance of mood:
 - Ambivalence
 - Inappropriate or constricted affective responses
 - Disturbance of behaviour:
 - Apathetic withdrawal
 - Bizarre activity
- Patients may present with positive or negative symptoms:
 - Positive symptoms:
 - Conceptual disorganisation
 - Delusions (false belief, based on incorrect inference about external reality, not consistent with patient's intelligence and cultural background)
 - Hallucinations (false sensory perception not associated with real external stimuli)
 - In contrast to illusion which is a misperception or misinterpretation of real external sensory stimuli
 - Negative symptoms:
 - Predominate in one-third of patients
 - Associated with poor long-term outcome and poor response to drug treatment
 - Consist of:
 - Loss of function
 - Anhedonia
 - Decreased emotional expression
 - Impaired concentration
 - Diminished social engagement
 - o The patient must have at least two of these for a 1-month period and continuous signs for six months to meet the formal diagnostic criteria

EPIDEMIOLOGY

- Lifetime prevalence of the disease is about 1%
- Equally prevalent between men and women
- Peak age of onset is between 15 and 35 (with 50% cases before age 25)
- Persons born in winter are more likely to develop the disease than those born in spring or summer

- o There is an increased rate among babies born to mothers who have influenza during pregnancy
- There is a higher mortality rate from accidents and natural causes than in the general population
 - o Leading cause of death in schizophrenic patients is suicide
 - Over 40% of schizophrenic patients abuse drugs and alcohol
- It is more common in lower rather than higher socio-economic groups

PATHOPHYSIOLOGY AND AETIOLOGY:

- The stress diathesis model is often used:
 - O Person in whom schizophrenia develops has a specific biological vulnerability (*diathesis*) that is triggered by stress and leads to schizophrenic symptoms
- The stresses may be genetic, biological, psychosocial or environmental:
 - o **GENETIC**:
 - Both single gene and polygenic theories have been put forward
 - Consanguinity:
 - Incidence in these families is higher than in the general population
 - Concordance is higher in MZ twin studies than DZ (45-50% vs 12-15%)
 - Adoption studies:
 - The prevalence of schizophrenia is greater in the biologic parents of schizophrenic adoptees than in adoptive parents
 - MZ twins raised apart have the same concordance rate as twins reared together
 - Rates of schizophrenia are not increased in children born to unaffected parents but raised by a schizophrenic parent

BIOLOGICAL:

- DOPAMINE HYPOTHESIS:
 - The **mesolimbic** dopaminergic system has it origins in cell bodies of the **ventral tegmental area (VTA)**
 - These project to the limbic system, nucleus accumbens, ventral striatum and parts of the amygdala and hippocampus
 - Overactivity of this system accounts for the positive symptoms of schizophrenia:
 - The **mesocortical** dopaminergic system originates in VTA and projects to neocortex (particularly prefrontal)
 - Responsible for temporal organization of behaviour, motivation, planning, attention and social behaviour
 - o **Underactivity** of this system accounts for the negative symptoms of schizophrenia
 - The theory is based upon the psychotogenic effects of drugs that increase dopamine levels (amphetamines and

cocaine) and the antipsychotic effects of dopamine receptor antagonists

- NORADRENALINE HYPOTHESIS:
 - Increased noradrenaline levels in schizophrenia lead to increased sensitisation to sensory input
- GABA HYPOTHESIS:
 - Decreased GABA activity increases dopamine activity
- SEROTONIN HYPOTHESIS:
 - Abnormalities in serotonin metabolism have been reported, with both high and low levels being found
 - Specifically, antagonism at the 5HT2 receptor has been emphasised as important in reducing psychotic symptoms
- GLUTAMATE HYPOTHESIS:
 - Hypofunction of NMDA receptor
- NEURODEVELOPMENTAL THEORIES:
 - Abnormal neuronal migration during the second trimester of foetal development
 - Abnormal neuronal functioning may lead to the emergence of symptoms during adolescence

PSYCHOSOCIAL AND ENVIRONMENTAL:

- Family factors:
 - Patients whose families have high levels of **expressed emotion** (EE any overly involved, intrusive behaviour, be it hostile and critical or controlling and infantilising) have higher relapse rates
 - o Relapse rates are lowered when behaviour is modified to lower EE
 - Most observers believe that family dysfunction is a consequence, rather than a cause, of schizophrenia
- Other psychodynamic factors:
 - Knowing what psychological and environmental stresses are most likely to trigger psychotic decompensation in a patient helps the clinician address these issues supportively

DIAGNOSIS, SIGNS AND SYMPTOMS:

- DSM-IV criteria for schizophrenia:
 - o Characteristic symptoms (two or more) are present for a significant portion of time during a 1-month period:
 - Delusions
 - Hallucinations (most frequently auditory)
 - Disorganised speech (frequent derailment or incoherence)
 - Grossly disorganised or catatonic behaviour
 - Negative symptoms (affective flattening, alogia or avolition)

- NB only one of these symptoms are required if delusions are bizarre or hallucinations consist of voice keeping running commentary of person's actions
- Social or occupational dysfunction (compared to the period prior to onset)
- o **Duration**. Needs to be continuous of disturbance for at least six months
- Schizoaffective and mood disorder exclusion:
 - No major manic, depressive or mixed episodes have occurred concurrently with the active-phase symptoms
- Substance/general medical condition exclusion

• Otherwise:

- Affect is abnormal (blunted, flat, labile, inappropriate)
- Sense of self is disturbed
- o Interpersonal functioning is impaired:
 - Social withdrawal
 - Emotional detachment
 - Aggressiveness
 - Sexual inappropriateness
- Cognition is impaired:
 - Inattention
 - Impaired information processing

DIFFERENTIAL DIAGNOSIS:

- MEDICAL AND NEUROLOGIC DISORDERS:
 - o Substance intoxication (particularly cocaine and phenylcyclidine)
 - o CNS infections
 - o SLE
 - o Temporal lobe epilepsy
 - o Degenerative disease (e.g. Huntingtons)
- SCHIZOPHRENIFORM DISORDER:
 - Symptoms may be identical to those of schizophrenia but last for less than six months
 - o Deterioration is less pronounced and prognosis is better
- BRIEF PSYCHOTIC DISORDER:
 - Symptoms last for less than one month and proceed from a clearly defined psychosocial stress
- MOOD DISORDER:
 - Both manic episodes and major depressive episodes of bipolar I disorder and major depressive disorder may present with psychotic features
 - o This differential diagnosis is particularly important because of the availability of specific and effective treatments for the mood disorders
- SCHIZOAFFECTIVE DISORDER:
 - Mood symptoms develop concurrently with symptoms of schizophrenia, but delusions or hallucinations must be present for 2 weeks in the absence of prominent mood symptoms during some stage of the illness

- DELUSIONAL DISORDER:
 - o Relatively intact, well functioning personality
- PERSONALITY DISORDER:
 - o Generally no psychotic features (may be transient)
- FACTITIOUS OR MALINGERING DISORDER:
 - o Patient is feigning the symptoms
 - Clear secondary gain (malingering)
 - Deep psychological motivation (factitious)

TREATMENT:

- PHARMACOLOGIC:
 - o Choice of drug is important:
 - Dopamine receptor antagonists (typical antipsychotics):
 - Effective in treatment of positive symptoms:
 - High potency agents (e.g. haloperidol) are most likely to cause EPS:
 - Akathisia
 - o Acute dystonia
 - o Pseudoparkinsonism
 - Low potency agents (e.g. chlorpromazine) are more sedating, hypotensive and anticholinergic
 - These agents (collectively) can cause **tardive dyskinesia** at rate of 5% per year of exposure
 - A significant portion of patients are either unresponsive to or intolerant of these drugs
 - As a result, the newer, second generation antipsychotic agents are usually employed as first line agents
 - Serotonin-dopamine antagonists (atypical, novel or secondgeneration antipsychotics):
 - Provide potent 5-HT2-receptor blockade and varying degrees of D2 blockade.
 - In comparison with dopamine receptor antagonists, these drugs improve two classes of disabilities typical of schizophrenia:
 - o Positive AND negative symptoms
 - Cause fewer EPS
 - Do not elevate prolactin levels
 - Less likely to cause tardive dyskinesia
 - Can be highly sedating and cause weight gain
 - Included amongst this group:
 - Risperidone
 - o Olanzapine
 - o Clozapine (1% risk of agranulocytosis)
 - Maintenance:

- Long-term treatment with antipsychotic medication is usually required to decrease the risk for relapse
- If the patient has been stable for one year, the dose can be decreased to the minimum effective dosage

• ELECTROCONVULSIVE THERAPY (ECT):

- o Can be effective for acute psychosis and catatonic subtype
- Also promising for refractory positive symptoms

• PSYCHOSOCIAL TREATMENTS:

- Antipsychotic medication alone is not sufficient in treating schizophrenic patients
- Behaviour therapy:
 - Desired behaviour is positively reinforced with rewards
- Group therapy:
 - Focus is on support and social skills development (ADLs etc)
 - Helpful in decreasing isolation and increasing reality testing

Family therapy:

 High EE family interactions can be diminished through family therapy, thereby decreasing relapse rates

Supportive psychotherapy:

- Traditional, insight-oriented therapy is not recommended, as egos of patients are too fragile.
- Supportive therapy may include:
 - Advice
 - Reassurance
 - Education
 - Modelling
 - Limit setting
 - Reality testing

o Social skills training:

o Case management:

- Responsible for the patient's concrete needs and coordination of care
- Participate in treatment planning and communication between various providers
- Help patients:
 - Make appointments
 - Obtain housing
 - Obtain financial benefits
 - Navigate the health care system (advocacy)

Support groups